Appeals Court Nixes Savient Injunction Bid
A federal appeals court has dealt a blow to Savient Pharmaceuticals Inc., opening the market for Savient's $60 million weight control drug Oxandrin to generic competition....To view the full article, register now.
Already a subscriber? Click here to view full article